Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Shares Outstanding (Weighted Average) (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Shares Outstanding (Weighted Average) for 15 consecutive years, with $79.2 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Weighted Average) rose 4.28% to $79.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $79.2 million through Dec 2025, up 4.28% year-over-year, with the annual reading at $79.2 million for FY2025, 4.28% up from the prior year.
  • Shares Outstanding (Weighted Average) for Q4 2025 was $79.2 million at Niagen Bioscience, roughly flat from $79.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Weighted Average) was $79.2 million in Q4 2025, with the low at $64.2 million in Q1 2021.
  • Average Shares Outstanding (Weighted Average) over 5 years is $72.8 million, with a median of $74.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Weighted Average) increased 10.6% in 2021, then rose 0.16% in 2022.
  • Over 5 years, Shares Outstanding (Weighted Average) stood at $67.2 million in 2021, then rose by 3.79% to $69.7 million in 2022, then grew by 7.54% to $75.0 million in 2023, then grew by 1.26% to $75.9 million in 2024, then increased by 4.28% to $79.2 million in 2025.
  • According to Business Quant data, Shares Outstanding (Weighted Average) over the past three periods came in at $79.2 million, $79.0 million, and $78.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.